Augmenting Cognitive Function in the Elderly with Mild Cognitive Impairment Using Probiotic Lacticaseibacillus rhamnosus CBT-LR5: A 12-Week Randomized, Double-Blind, Parallel-Group Non-Comparative Study

被引:0
|
作者
Jung, Su-Jin [1 ,2 ]
Cho, Kyohee [3 ]
Jung, Eun-Soo [1 ]
Son, Dooheon [3 ]
Byun, Jong-Seon [3 ]
Kim, Song-In [3 ]
Chae, Soo-Wan [1 ,2 ]
Yang, Jong-Chul [1 ,2 ,4 ]
Lee, Seung-Ok [1 ,2 ,5 ,6 ]
Lim, Sanghyun [3 ]
机构
[1] Jeonbuk Natl Univ Hosp, Clin Trial Ctr Funct Foods, Jeonju 54907, South Korea
[2] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr K FOOD Microbiome, Jeonju 54907, South Korea
[3] Cell Biotech Co Ltd, R&D Ctr, Gimpo Si 10003, South Korea
[4] Jeonbuk Natl Univ, Med Sch, Dept Psychiat, Jeonju 54896, South Korea
[5] Jeonbuk Natl Univ Hosp, Dept Gastroenterol & Hepatol, Jeonju 54896, South Korea
[6] Jeonbuk Natl Univ, Med Sch, Dept Internal Med, Jeonju 54896, South Korea
关键词
mild cognitive impairment (MCI); <italic>Lacticaseibacillus rhamnosus</italic> CBT-LR5; skim milk; probiotics; cognitive function; clinical trial; GUT-BRAIN AXIS; BIOACTIVE PEPTIDES; FERMENTED MILK; MICROBIOTA; MEMORY; EDUCATION; DEMENTIA;
D O I
10.3390/nu17040691
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Probiotics have been shown to enhance cognitive function in individuals with mild cognitive impairment (MCI), but their efficacy varies, depending on the strain and dosage. Objectives: Clinical investigations are crucial to confirm their safety, efficacy, and mechanism of action. This study was designed to assess the effective dosage, safety, and efficacy of MH-Pro, a test product containing Lacticaseibacillus rhamnosus CBT-LR5 (LR5) and skim milk (non-fat dry milk), in improving cognitive function and related physiological changes in older adults suspected of MCI over 12 weeks. Methods: In total, 20 participants (mean age: 68.9 years) were randomly assigned in a 1:1 ratio to either a low-dose group (1 x 1010 CFU LR5 with 1622 mg) or a high-dose group (1 x 1010 CFU LR5 with 4055 mg skim milk) in a double-blind, parallel-group clinical trial. Results: After 12 weeks, the low-dose group showed significant improvements in the MOCA-K subdomains, specifically in naming (p = 0.01) and delayed recall (p = 0.003). Additionally, levels of amyloid-beta 1 40/42 in the blood significantly decreased (p = 0.03) following supplementation in the low-dose group. The high-dose group exhibited significant improvement in orientation (p = 0.05). Moreover, overall cognitive enhancement was observed in the low-dose group (p = 0.003), while the high-dose group showed a trend toward improvement (p = 0.06). Fecal analysis revealed significant changes in bacterial composition, with an increase in Lacticaseibacillus after 12 weeks of MH-Pro consumption. Together, these findings provide foundational evidence suggesting that MH-Pro supplementation may serve as a potential intervention for enhancing cognitive function through gut-brain axis pathways in the elderly population. However, given the small sample size and the predominance of female participants, the impact of the outcome may be limited. Further large-scale studies are necessary to validate these preliminary results. Conclusions: This study provides foundational evidence to recognize the use of LR5 and skim milk to prepare a probiotic supplement that enhances cognitive function in the aging population.
引用
收藏
页数:19
相关论文
共 38 条
  • [21] Efficacy and Tolerability of Atorvastatin/Fenofibrate Fixed-Dose Combination Tablet Compared With Atorvastatin and Fenofibrate Monotherapies in Patients With Dyslipidemia: A 12-Week, Multicenter, Double-Blind, Randomized, Parallel-Group Study
    Davidson, Michael H.
    Rooney, Michael W.
    Drucker, Joan
    Griffin, H. Eugene
    Oosman, Sonia
    Beckert, Michael
    CLINICAL THERAPEUTICS, 2009, 31 (12) : 2824 - 2838
  • [22] A 12-WEEK, DOUBLE-BLIND, RANDOMIZED, FORCED TITRATION, PARALLEL-GROUP STUDY TO ASSESS THE EFFECTS OF NAPROXCINOD AND NAPROXEN ON ARTERIAL BLOOD PRESSURE AS MEASURED BY ABPM IN OSTEOARTHRITIS PATIENTS WITH CONTROLLED ESSENTIAL HYPERTENSION
    Townsend, R. R.
    Bakris, G. L.
    Erdy, G.
    Hazan, L.
    Hall, C.
    Longlade, P.
    Fleming, R.
    Djian, J.
    JOURNAL OF HYPERTENSION, 2009, 27 : S7 - S7
  • [23] Cognitive Improvement and Safety Assessment of a Dietary Supplement Containing Propolis Extract in Elderly Japanese: A Placebo-Controlled, Randomized, Parallel-Group, Double-Blind Human Clinical Study
    Asama, Takashi
    Hiraoka, Toshihito
    Ohkuma, Akio
    Okumura, Nobuaki
    Yamaki, Ayanori
    Urakami, Katsuya
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2021, 2021
  • [24] Efficacy of Probiotic Supplements on Brain-Derived Neurotrophic Factor, Inflammatory Biomarkers, Oxidative Stress and Cognitive Function in Patients with Alzheimer's Dementia: A 12-Week Randomized, Double-Blind Active-Controlled Study
    Hsu, Yu-Chieh
    Huang, Yen-Yu
    Tsai, Shin-Yu
    Kuo, Yi-Wei
    Lin, Jia-Hung
    Ho, Hsieh-Hsun
    Chen, Jui-Fen
    Hsia, Ko-Chiang
    Sun, Yu
    NUTRIENTS, 2024, 16 (01)
  • [25] Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in Chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study
    Hsieh, Sheng-Hwu
    Lin, Jen-Der
    Chang, Hung-Yu
    Ho, Cheng
    Liou, Miaw-Jene
    CLINICAL THERAPEUTICS, 2006, 28 (09) : 1318 - 1326
  • [26] The effect of 24-week continuous intake of quercetin-rich onion on age-related cognitive decline in healthy elderly people: a randomized, double-blind, placebo-controlled, parallel-group comparative clinical trial
    Nishihira, Jun
    Nishimura, Mie
    Kurimoto, Masanori
    Kagami-Katsuyama, Hiroyo
    Hattori, Hiroki
    Nakagawa, Toshiyuki
    Muro, Takato
    Kobori, Masuko
    JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2021, 69 (02) : 203 - 215
  • [27] Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: a Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study (Jul, 10.1080/07315724.2021.1962770, 2021)
    Shiojima, Y.
    Takahashi, M.
    Takahashi, R.
    Moriyama, H.
    Bagchi, D.
    Bagchi, M.
    Akanum, M.
    JOURNAL OF THE AMERICAN NUTRITION ASSOCIATION, 2022, 41 (08): : 855 - 855
  • [28] A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12-WEEK STUDY OF ENCENICLINE, AN A7 NICOTINIC ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, FOR COGNITIVE IMPAIRMENT IN PATIENTS WITH SCHIZOPHRENIA
    Lombardo, Ilise
    Dgetluck, Nancy
    Koenig, Gerhard
    Loewen, Gordon
    Hilt, Dana
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S321 - S321
  • [29] Effect of 12-Week Daily Intake of the High-Lycopene Tomato (Solanum Lycopersicum), a Variety Named "PR-7", on Lipid Metabolism: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
    Nishimura, Mie
    Tominaga, Naoki
    Ishikawa-Takano, Yuko
    Maeda-Yamamoto, Mari
    Nishihira, Jun
    NUTRIENTS, 2019, 11 (05):
  • [30] Efficacy and Tolerability of Fimasartan, a New Angiotensin Receptor Blocker, Compared With Losartan (50/100 mg): A 12-Week, Phase III, Multicenter, Prospective, Randomized, Double-Blind, Parallel-Group, Dose Escalation Clinical Trial With an Optional 12-Week Extension Phase in Adult Korean Patients With Mild-to-Moderate Hypertension
    Lee, Sang Eun
    Kim, Yong-Jin
    Lee, Hae-Young
    Yang, Han-Mo
    Park, Chang-Gyu
    Kim, Jae-Joong
    Kim, Soon-Kil
    Rhee, Moo-Yong
    Oh, Byung-Hee
    CLINICAL THERAPEUTICS, 2012, 34 (03) : 552 - 568